RenovoRxRNXT 31 Days Payable is 1,041.77 as of Mar. 2026, which is 35% above its 10-year median of 772.97. GuruFocus rates RNXT with a GF Score™ of 31/100. The stock has 2 warning signs investors should review. Among 707 Biotechnology companies, RenovoRx ranks better than 86.28% on this metric.
RenovoRx's average Accounts Payable for the
three
months ended in Mar. 2026 was $0.96 Mil. RenovoRx's Cost of Goods Sold for the
three
months ended in Mar. 2026 was $0.08 Mil.
Hence, RenovoRx's Days Payable for the
three
months ended in Mar. 2026 was 1,041.77.
The historical rank and industry rank for RenovoRx's Days Payable or its related term are showing as below:
RNXT'
s Days Payable Range Over the Past 10 Years
Min: 772.97 Med: 772.97 Max: 1019.01
Current: 1019.01
During the past 7 years, RenovoRx's highest Days Payable was 1019.01. The lowest was 772.97. And the median was 772.97.
RNXT's Days Payable is ranked better than 86.28% of 707
companies
in the Biotechnology industry
Industry Median: 113.76
vs RNXT: 1019.01
RenovoRx's Days Payable
increased
from Mar. 2025 (753.78) to Mar. 2026 (1,041.77).
It may suggest that RenovoRxdelayed paying its suppliers.
RenovoRx Days Payable Related Terms
RenovoRx Days Payable Historical Data
* Premium members only.
The historical data trend for RenovoRx's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, RenovoRx's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RenovoRx Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, RenovoRx's Days Payable distribution charts can be found below:
* The bar in red indicates where RenovoRx's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
RenovoRx's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RenovoRx (RNXT) has a Days Payable of 1,041.77 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on RenovoRx and its competitors. This is 35% above median its historical median of 772.97. Over the past decade, RenovoRx's Days Payable has ranged from 772.97 to 1,019.01. According to the industry distribution chart, RenovoRx ranks #97 out of 707 companies in the Biotechnology industry, placing it in the top 13.7%.
Is RenovoRx's Days Payable too high?
RenovoRx's current Days Payable of 1,041.77 is 35% above median its 10-year median of 772.97. Over the past 10 years, this metric has ranged from a low of 772.97 to a high of 1,019.01. The Biotechnology industry median Days Payable is 113.76. RenovoRx's value of 1,041.77 is 815.8% above this industry median. Based on the distribution chart, RenovoRx ranks #97 out of 707 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, RenovoRx has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does RenovoRx's Days Payable compare to NNVC and KALA?
According to the Biotechnology industry distribution chart, RenovoRx ranks #97 out of 707 companies for Days Payable. This places RenovoRx in the top 14% of its industry — outperforming the majority of peers. The industry median Days Payable is 113.76. RenovoRx's value of 1,041.77 is 815.8% above this benchmark. Historically, RenovoRx's own Days Payable has ranged from 772.97 to 1,019.01 over the past decade. While the company's 10-year median is 772.97 vs. the industry median of 113.76, RenovoRx has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.76, based on 707 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RenovoRx's current Days Payable of 1,041.77 is 815.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on RenovoRx and its competitors. For the Biotechnology industry, the median Days Payable is 113.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RenovoRx's current Days Payable is 1,041.77, which is 35% above median its own 10-year median of 772.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RenovoRx stock overvalued right now?
RenovoRx (RNXT) has a current Days Payable of 1,041.77. The current Days Payable is 1,041.77, which is 35% above median its 10-year median of 772.97 and 815.8% above the Biotechnology industry median of 113.76. RenovoRx's overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For RenovoRx (RNXT), the current Days Payable is 1,041.77 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
31GF Score
Get the complete analysis for RNXT
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RNXT has been successfully added to your 
